For years, people experimenting with chlorine dioxide have reported something that sounds almost impossible. Some people diagnosed with Parkinson’s disease say their tremors diminished. Others describe improvements in movement, rigidity, walking, balance, speech, or everyday function.
And among the strongest testimonials are people who say, in effect: “I had Parkinson’s. I was told I would have it for the rest of my life. Now it is gone.” Those are extraordinary claims. They are also anecdotes.
We don’t have controlled clinical trials demonstrating that chlorine dioxide treats, reverses, or cures Parkinson’s disease. We don’t have systematic before-and-after neurological examinations documenting these reports. And because people frequently make other changes at the same time, chlorine dioxide may receive credit for something it didn’t cause.
So why discuss the reports at all? Because while investigating them, we run into something remarkable. Scientists studying Parkinson’s disease are increasingly looking somewhere we might not have expected: the gut. And some of the newest research suggests that changing what happens in the gut may actually change measurable features of Parkinson’s disease.
That doesn’t prove anything about chlorine dioxide. But it gives us a fascinating new question to investigate.
Parkinson’s Is More Than a Tremor
Parkinson’s disease is a progressive neurological disorder involving the loss or dysfunction of dopamine-producing neurons, particularly within an area of the brain called the substantia nigra.
The familiar symptoms can include:
- tremor
- slowed movement
- stiffness
- balance problems
- changes in walking
- speech difficulties
But Parkinson’s extends far beyond movement. Sleep, smell, mood, digestion and the autonomic nervous system can also be involved.
Another important part of Parkinson’s biology is a protein called alpha-synuclein, often abbreviated α-synuclein. In Parkinson’s, abnormal forms of this protein can accumulate and aggregate within the nervous system.
For decades, it seemed logical to concentrate almost entirely on what was happening inside the brain. Then researchers began paying much closer attention to what had been happening to many patients before their hands ever started shaking.
Before the Tremor, There May Have Been a Gut Story
Constipation is extraordinarily interesting in Parkinson’s disease. Not simply because Parkinson’s patients frequently develop constipation. Sometimes constipation comes first.
A systematic review and meta-analysis involving more than 740,000 participants found that constipation was associated with more than twice the odds of subsequently developing Parkinson’s disease. Importantly, the association remained when researchers examined constipation occurring more than 10 years before Parkinson’s diagnosis.
Later research involving more than three million participants also found a significant association between constipation and prodromal Parkinson’s disease. That doesn’t mean constipation causes Parkinson’s. Most people with constipation won’t develop Parkinson’s.
But it raises a fascinating question: Why can a gastrointestinal problem appear years before the neurological disease becomes obvious?
Enter the Gut-Brain Axis
The gastrointestinal tract and brain aren’t two completely independent systems. The intestinal nervous system, immune system, microbial ecosystem and brain communicate continuously.
Scientists call this interconnected communication network the Microbiome–Gut–Brain Axis, and Parkinson’s researchers are now studying it intensely.
A 2024 review describes Parkinson’s as involving both the central nervous system and the enteric nervous system—the enormous network of neurons associated with the gastrointestinal tract. The authors emphasize that important questions remain unanswered, including exactly how early the gut becomes involved and whether it initiates disease in some patients.
More recent reviews investigate possible relationships among:
gut dysbiosis → intestinal barrier dysfunction → microbial metabolites → immune activation → inflammation → α-synuclein pathology → neuroinflammation
These are active areas of research rather than a completed explanation of Parkinson’s disease. Still, we have traveled quite a distance from thinking Parkinson’s is simply a problem isolated inside the brain.
Could Parkinson’s Sometimes Begin in the Gut?
This is where the story gets particularly interesting. Researchers have proposed that Parkinson’s may not begin in exactly the same place in everyone. One contemporary model describes two broad patterns:
Brain-First Parkinson’s
Pathology may begin primarily within the brain and subsequently spread through other parts of the nervous system.
Body-First Parkinson’s
Pathology may begin within the peripheral nervous system—including potentially the enteric nervous system—and subsequently progress toward the brain.
A 2024 review of the evidence found support for aspects of this model, including clusters of symptoms associated with the proposed body-first subtype, such as constipation, REM-sleep behavior disorder, and autonomic dysfunction. Some imaging and pathology findings support the model, while other evidence remains conflicting.
That’s an important qualification. We shouldn’t replace the old oversimplification — “Parkinson’s starts in the brain.” — with a new one — “Parkinson’s starts in the gut.”
A better statement is:
Parkinson’s may represent more than one biological pathway, and the gastrointestinal system may play an important role in at least some of them.
The Alpha-Synuclein Trail
Alpha-synuclein makes the gut-first hypothesis even more intriguing. Researchers are investigating whether abnormal α-synuclein can arise within the enteric nervous system and participate in a chain of events eventually involving the brain.
One proposed route involves the vagus nerve, an important communication highway connecting internal organs with the brain.
The proposed sequence looks something like:
intestinal disturbance
↓
microbiome changes
↓
intestinal inflammation / barrier dysfunction
↓
abnormal α-synuclein biology
↓
enteric nervous system
↓
vagal pathways
↓
central nervous system
↓
neuroinflammation and neuronal dysfunction
Current research reviews describe versions of this pathway, but the precise direction, triggers, and causal relationships remain under investigation. Then, in 2026, researchers did something particularly interesting.
What Happens If Researchers Actually Change the Gut Microbiome?
Rather than simply observing that people with Parkinson’s have different gut microbes, researchers conducted a randomized, double-blind phase 2 clinical trial involving 72 newly diagnosed Parkinson’s patients who had not yet received dopaminergic Parkinson’s medication.
One group received repeated fecal microbiota transplantation from donors. The comparison group received their own microbiota. Sixty-six participants completed the 35-week trial.
The donor-FMT group improved by an average 3.8 points on the UPDRS III motor examination, while the comparison group changed by +0.1 points. Constipation also improved substantially more in the donor-FMT group.
That’s interesting by itself. But the biological measurements make the study even more intriguing.
Researchers observed changes in the microbiome, improved measures of intestinal-barrier integrity and decreased phosphorylated α-synuclein in colon biopsies. Changes in Escherichia-Shigella abundance correlated with changes in colonic α-synuclein.
This does not mean FMT cures Parkinson’s. It was a relatively small, single-center phase 2 study. It needs independent replication, longer follow-up, and further investigation. But it demonstrates something extremely relevant to our question:
Changing the intestinal microbial ecosystem was followed by measurable changes in both gastrointestinal and Parkinson’s motor outcomes in a controlled human experiment.
That is considerably more compelling than simply discovering different bacteria in Parkinson’s patients.

Now Let’s Bring Chlorine Dioxide Back Into the Conversation
Chlorine dioxide has established antimicrobial and oxidative chemistry. What has not been established is that chlorine dioxide beneficially modifies the Parkinson’s microbiome or treats Parkinson’s disease. That’s the missing bridge.
But suppose, strictly as a research hypothesis, that some of the reports surrounding chlorine dioxide are genuine.
Instead of imagining:
chlorine dioxide → travels to the substantia nigra → repairs Parkinson’s
we might investigate something more like:
chlorine dioxide exposure
↓
?
↓
intestinal microbial environment
↓
intestinal barrier / microbial metabolites
↓
immune and inflammatory signaling
↓
α-synuclein-related biology
↓
gut-brain communication
↓
neurological manifestations
The enormous question mark is intentional.
We don’t know what’s happening there—or whether anything clinically useful is happening at all.
But now we have something scientists could actually test.
Antimicrobial Doesn’t Automatically Mean Beneficial
This distinction is particularly important.
Chlorine dioxide’s antimicrobial properties do not establish that it would improve a disturbed microbiome.
The intestinal microbiome contains enormous numbers of organisms participating in normal physiology.
Killing or suppressing microorganisms indiscriminately could potentially be detrimental.
So the hypothesis cannot simply be: Parkinson’s involves microbes + chlorine dioxide kills microbes = chlorine dioxide treats Parkinson’s. Biology isn’t that simple.
Researchers would need to determine whether chlorine dioxide exposure changes microbial composition at all under the conditions being reported—and, if so, which organisms and microbial functions change.
Then they would need to determine whether those changes affect intestinal permeability, metabolites, inflammatory signaling, α-synuclein biology, or anything else relevant to Parkinson’s.
Oxidation Creates Another Important Question
There’s another reason to resist an overly simple explanation. Oxidative stress is already implicated in Parkinson’s disease.
Therefore: Parkinson’s involves oxidative stress + chlorine dioxide is an oxidizer doesn’t logically lead to: chlorine dioxide fixes Parkinson’s. Quite the opposite could be possible depending on concentration, location, and biological context.
The useful research question is more specific:
Does chlorine dioxide’s chemistry produce an indirect biological change that could explain any of the reported neurological observations without causing offsetting oxidative injury?
That’s measurable.
Inflammation May Be Another Piece of the Puzzle
Neuroinflammation is another major area of Parkinson’s research. And once again, the gut may participate.
Microbial products can interact with the immune system. Intestinal-barrier dysfunction can change exposure to microbial components. Immune signaling can become systemic, and researchers are investigating how these processes interact with inflammation within the nervous system and α-synuclein pathology.
So if a chlorine dioxide-associated change were ever demonstrated, researchers shouldn’t measure only tremor. They should measure what happened upstream.

How Herb Roi Richards Interprets the Reports
Herb Roi Richards, author of Chlorine Dioxide for Humans: Recipes & Treatment, approaches Parkinson’s disease from a different direction.
Based on the reports and field experiences he has collected, Richards proposes that chlorine dioxide may help by breaking down what he describes as heavy metals, microbial waste, and other irritants affecting brain and nerve tissue. In his framework, reducing this burden allows the body’s neurological environment to regain balance, potentially allowing electrical signaling to function more normally and tremors to diminish.
It is an interesting hypothesis—but several parts of it have not been established scientifically.
There is evidence connecting Parkinson’s disease with environmental exposures, neuroinflammation, oxidative stress, gut microbial changes, and altered intestinal-barrier function. There is also substantial research investigating metals and environmental toxicants as possible contributors to Parkinson’s risk and pathology. But that does not scientifically establish that chlorine dioxide removes heavy metals from human neurological tissue or that an “oxidative cleanup” restores neuronal electrical signaling in Parkinson’s patients.
Richards’ explanation should therefore be understood as his working field model, rather than an established mechanism.
What makes the model interesting in light of emerging research isn’t necessarily the idea that chlorine dioxide travels into the brain and cleans it. The more intriguing possibility may again be upstream:
intestinal environment → microbial products → intestinal barrier → immune signaling → systemic inflammation → neuroinflammation → neurological function
If chlorine dioxide really does account for some of the reported changes, researchers could determine whether anything along that pathway changes before neurological improvement occurs.
What Herb Actually Recommends
Richards’ approach isn’t limited to chlorine dioxide. His Parkinson’s protocol combines chlorine dioxide with nutritional, mineral, topical, and lifestyle measures.
In Chlorine Dioxide for Humans, he describes an oral chlorine dioxide schedule involving activated drops taken repeatedly during the day, along with a diluted topical compress applied to the neck or spinal area. He also discusses magnesium chloride and gentle stretching, and lists companion products including aloe vera, apple cider vinegar, flaxseed oil, Lugol’s iodine, and Epsom-salt baths.
That distinction matters.
If someone following Richards’ program subsequently improves, scientifically, we cannot automatically say: “Chlorine dioxide did it.” There are multiple interventions occurring simultaneously.
Magnesium, for example, has established roles in normal neuromuscular and nervous-system physiology. Exercise and physical therapy also have established roles in maintaining mobility, balance, flexibility, and function in Parkinson’s disease.
Other components of Richards’ regimen have very different evidence bases and proposed purposes. Consequently, the complete protocol creates both an interesting observation and a scientific attribution problem.
One Protocol, Several Testable Questions
Rather than accepting or rejecting the entire package, researchers could separate it.
- Did chlorine dioxide exposure change anything measurable?
- Did the microbiome change?
- Did inflammatory markers change?
- Did gastrointestinal function change?
- Did magnesium status change?
- Did physical activity or flexibility improve?
- Did medication requirements change?
- Did objective Parkinson’s scores change?
- And which change happened first?
That approach respects the observations without requiring researchers to accept Richards’ explanation beforehand.
“My Parkinson’s Is Gone” Is the Beginning of the Investigation
When someone reports that their Parkinson’s disappeared, it’s tempting either to celebrate the story as proof or dismiss it as impossible. Neither response teaches us very much. Instead, ask questions.
- Was Parkinson’s formally diagnosed?
- By whom?
- How long had the person had it?
- What symptoms were documented?
- Was the person taking levodopa or another Parkinson’s medication?
- Did medication change simultaneously?
- What exactly improved?
- Did tremor disappear?
- Did bradykinesia improve?
- Did rigidity change?
- What happened to walking and balance?
- Was improvement confirmed by a neurologist?
- Did UPDRS scores change?
And most importantly:
- Did the improvement last?
Those details transform a testimonial into the beginning of a case history.
Parkinson’s Disease Isn’t the Same as Parkinsonism
This distinction could prove extremely important when reviewing historical reports.
- A person can exhibit tremor, rigidity, slowed movement, and walking difficulties without having idiopathic Parkinson’s disease.
- Drug-induced parkinsonism, vascular parkinsonism, atypical parkinsonian disorders, and other neurological conditions can produce overlapping symptoms.
- Essential tremor can also be mistaken by patients for Parkinson’s.
Consequently, reports should ideally be divided into categories:
-
- Neurologist-confirmed Parkinson’s disease
- Probable Parkinson’s disease
- Other diagnosed parkinsonism
- Self-reported Parkinson’s
- Diagnosis uncertain
If the dramatic outcomes concentrate primarily among people with uncertain diagnoses, that tells us something. If they remain among people with well-documented progressive Parkinson’s disease, that tells us something considerably more interesting.
The Testimonials Could Become Data
Suppose there really are hundreds—or thousands—of these reports accumulated through the chlorine dioxide community.
Don’t begin by trying to prove that chlorine dioxide cures Parkinson’s. Begin by organizing the observations.
A retrospective registry could record:
original diagnosis → duration of disease → original symptoms → medications → gastrointestinal history → constipation history → chlorine dioxide exposure → other interventions → time until reported change → objective neurological changes → medication changes → physician follow-up → duration of improvement
Then, obtain medical documentation where participants voluntarily provide it. That alone could reveal whether there’s actually a pattern.
Then Look for the Gut-First Signature
Here’s where this becomes particularly exciting. If researchers identified a group of unusually strong responders, they could ask:
Did these people have gastrointestinal symptoms years before Parkinson’s appeared?
- Did they have longstanding constipation?
- Inflammatory gastrointestinal problems?
- Unusual microbiome profiles?
- Evidence of altered intestinal permeability?
- Particular microbial metabolites?
- A phenotype resembling proposed body-first Parkinson’s?
Now we aren’t simply collecting testimonials. We’re testing a hypothesis.
Imagine the Prospective Study
The next step could be remarkably straightforward conceptually. Enroll people with carefully confirmed Parkinson’s disease.
Characterize them before anything happens.
Measure:
- UPDRS motor scores
- gait and movement
- tremor
- rigidity
- cognition
- smell
- sleep
- constipation and GI symptoms
- medications
- inflammatory biomarkers
- microbiome composition and function
- microbial metabolites
- intestinal-barrier markers
- α-synuclein biomarkers where validated and appropriate
- adverse effects
Then distinguish participants according to likely disease phenotype. And use appropriate controls and blinding.
- If nothing changes, we learn something.
- If symptoms change without microbiome changes, we learn something.
- If microbiome changes occur without neurological improvement, we learn something.
But if a reproducible sequence appeared —
microbiome changes first → intestinal/inflammatory biomarkers change → α-synuclein-related measures change → objective neurological function improves
— that would deserve serious attention.
Same Diagnosis. Different Roads?
This may eventually turn out to be one of the most important lessons. Just as osteoporosis can result from very different biological pathways, Parkinson’s disease may not be biologically identical in every patient.
Researchers are already exploring brain-first and body-first models. That could matter enormously when evaluating unconventional observations.
Perhaps an intervention could affect one pathway strongly while doing virtually nothing to another.
A clinical trial that lumps everybody together might see a weak average effect. A carefully stratified study might discover that a particular biological subgroup behaves differently. Or it might discover nothing at all. Either result advances our understanding.
Something May Have Happened Before the Brain
This investigation began with a difficult question: How could chlorine dioxide possibly make Parkinson’s disappear?
We still don’t know that it does. But we’ve discovered that the original question may be too narrow.
- Parkinson’s pathology isn’t confined to the brain.
- The enteric nervous system is involved.
- Constipation can precede diagnosis by more than a decade.
- The microbiome differs in Parkinson’s and is being investigated as part of disease biology.
- Researchers are actively studying gut-first and brain-first Parkinson’s.
- And now a randomized phase 2 human trial has shown that deliberately modifying the intestinal microbiome can be followed by measurable improvements in Parkinson’s motor symptoms, constipation, and biological markers in the colon.
None of that demonstrates that chlorine dioxide treats Parkinson’s disease. But it does something almost as valuable for an investigation: It gives us somewhere intelligent to look.
If repeated chlorine dioxide reports are merely coincidence, expectation, misdiagnosis, or another intervention receiving misplaced credit, careful investigation should reveal that. But if something reproducible really is happening, the microbiome–gut–brain axis gives researchers a plausible place to begin searching for it.
Not with: “Chlorine dioxide cures Parkinson’s.” But with: “What changed first?” And perhaps, before the tremor and long before anyone thought to look at the brain, there was already a story unfolding in the gut.
Selected Research & Further Reading
Zhang R, et al. Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson’s disease: a randomized phase 2 trial. Signal Transduction and Targeted Therapy, 2026. Seventy-two newly diagnosed, drug-naïve patients were randomized; donor FMT produced greater motor and gastrointestinal improvements at 35 weeks and was associated with microbiome, intestinal-barrier and colonic α-synuclein changes.
Adams-Carr KL, et al. Constipation preceding Parkinson’s disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry, 2016. Across nine studies and 741,593 participants, constipation was associated with subsequent Parkinson’s disease and could precede diagnosis by more than a decade.
The Gut-Brain Axis in Parkinson’s Disease, 2024. Reviews gastrointestinal dysfunction, enteric nervous-system involvement, gut α-synuclein, microbiome research and controversies concerning early gut involvement in Parkinson’s pathogenesis.
Brain-first vs. body-first Parkinson’s disease: An update on recent evidence, 2024. Reviews human imaging, clinical and pathological evidence for biologically different Parkinson’s trajectories.
The gut-brain axis in early Parkinson’s disease: from prodrome to prevention, 2025. Reviews early microbiome changes, intestinal inflammation, α-synuclein and experimental gut-directed approaches.
Parkinson’s disease and the gut-brain connection: unveiling pathways, mechanisms and promising therapies, 2025. Reviews microbiome–gut–brain mechanisms and emerging microbiome-directed therapeutic research.
Educational Notice
This article is for education and research discussion. Chlorine dioxide has not been clinically established as a treatment or cure for Parkinson’s disease, and inappropriate exposure can cause serious harm. Parkinson’s symptoms can also have multiple causes, and changes in symptoms should not be used as a reason to discontinue prescribed Parkinson’s medication without the clinician managing that treatment. The chlorine dioxide observations discussed here are presented as hypothesis-generating reports, not evidence of efficacy.




















